Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Editas Medicine
Editas Medicine
Editas sees clinical promise with new FDA pediatric disease tag for another blood disorder
Fierce Biotech
Tue, 04/26/22 - 10:15 pm
Editas Medicine
EDIT-301
CRISPR
beta thalassemia
Editas' gene-editing data has company touting prime time based on early vision improvement signals but questions remain
Fierce Biotech
Wed, 09/29/21 - 11:12 am
CRISPR
Editas Medicine
gene editing
EDIT-101
vision loss
Will Moderna Buy Editas Medicine to Jump Into Gene Editing?
Motley Fool
Thu, 08/12/21 - 11:22 am
Moderna Therapeutics
gene editing
Editas Medicine
M&A
After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact
Fierce Biotech
Wed, 02/10/21 - 10:27 am
AbbVie
Editas Medicine
CRISPR
Caribou Biosciences
gene editing
Former Biogen CEO Takes the Helm at Editas Medicine
BioSpace
Mon, 02/8/21 - 10:25 pm
Biogen
Editas Medicine
James Mullen
Pharma CEOs
Why Editas Medicine Stock Is Tumbling Today
Motley Fool
Mon, 01/11/21 - 06:50 pm
Editas Medicine
JPMHC 2021
EDIT-301
EDIT-101
AbbVie cuts Editas CRISPR pact it inherited from Allergan
Fierce Biotech
Fri, 08/7/20 - 10:52 am
Editas Medicine
Allergan
AbbVie
gene editing
CRISPR
Here's Why Editas Could Beat Intellia to a CRISPR Therapy
Motley Fool
Fri, 05/22/20 - 10:30 am
gene editing
CRISPR
Editas Medicine
Intellia
earnings
Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease
Motley Fool
Sun, 02/23/20 - 06:17 pm
beta thalassemia
rare disease
drug development
Acceleron
Bristol-Myers Squibb
Bluebird Bio
Sangamo Therapeutics
Vertex Pharmaceuticals
Editas Medicine
Syros Pharmaceuticals
Here's Why CRISPR Stocks Fell in January
Motley Fool
Wed, 02/5/20 - 10:07 am
Intellia Therapeutics
CRISPR Therapeutics
Editas Medicine
CRISPR
Overview: CRISPR Technology Headed to Clinical Trials
BioSpace
Wed, 01/8/20 - 10:33 am
CRISPR
Editas Medicine
clinical trials
Allergan
LCA10
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Motley Fool
Thu, 12/5/19 - 11:32 pm
Celgene
Editas Medicine
Juno Therapeutics
CRISPR
gene editing
More CRISPR Stock Catalysts Ahead
Motley Fool
Mon, 11/25/19 - 09:38 am
gene editing
CRISPR
Editas Medicine
Intellia Therapeutics
CRISPR Therapeutics
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Endpoints
Tue, 11/12/19 - 08:07 pm
Editas Medicine
Celgene
Juno Therapeutics
CRISPR
gene editing
immunotherapy
Editas Medicine Appoints Cynthia Collins President & CEO
Xconomy
Wed, 08/7/19 - 10:27 am
Editas Medicine
Editas, Allergan launch first in vivo study of CRISPR-based medicine
BioPharma Dive
Thu, 07/25/19 - 12:00 pm
Editas Medicine
Allergan
clinical trials
CRISPR
EDIT-101
Should Sangamo's Failure Make CRISPR Investors Nervous?
Motley Fool
Sun, 02/10/19 - 01:52 pm
Sangamo Therapeutics
gene editing
CRISPR
CRISPR Therapeutics
Editas Medicine
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
Xconomy
Tue, 01/22/19 - 11:57 pm
Editas Medicine
Katrine Bosley
CRISPR
FDA signs off on Editas CRISPR study on patients with a rare genetic disorder
Stat
Fri, 11/30/18 - 12:34 pm
CRISPR
Editas Medicine
FDA
Here's Why CRISPR Stocks Fell as Much as 40.7% in October
Motley Fool
Tue, 11/6/18 - 12:25 am
CRISPR
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
Pages
« first
‹ previous
1
2
3
next ›
last »